Company News

Exelixis and Ipsen start COSMIC-312 trial for advanced HCC

Exelixis and Ipsen have begun the Phase III COSMIC-312 trial of cabozantinib (cabometyx) in combination with atezolizumab (tecentriq) against sorafenib…